The field of nuclear medicine has seen significant advancements in radiotheranostics, particularly in neuroendocrine tumors (e.g., [68Ga]Ga/[177Lu]Lu-DOTATATE) and prostate cancer (e.g., [68Ga]Ga-prostate-specific membrane antigen [PSMA]–11, [18F]F-DCFPyL, and [177Lu]Lu-PSMA-617) (1). This evidence concerns the gene FOLH1 and prostate carcinoma.